Kan

Kan is a biotechnology company dedicated to discovering and developing small molecule therapeutics that modulate autophagy, the body's cellular recycling process. Founded by world-leading experts in autophagy, the company leverages a proprietary platform to identify novel targets and chemical leads that can restore or enhance autophagic flux. Kan's primary focus is on treating neurodegenerative diseases and cancers where autophagy dysfunction plays a critical role in disease progression. The company is backed by prominent life science investors, including The Column Group, and aims to translate fundamental biological insights into transformative medicines.